Edgewise Therapeutics Q1 2025: Assets $95.1M, Equity $95.2M
Ticker: EWTX · Form: 10-Q · Filed: May 8, 2025 · CIK: 1710072
| Field | Detail |
|---|---|
| Company | Edgewise Therapeutics, Inc. (EWTX) |
| Form Type | 10-Q |
| Filed Date | May 8, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: 10-Q, financials, quarterly-report
TL;DR
**Edgewise Q1 2025:** Assets $95.1M, Liabilities $0.33M, Equity $95.2M. Solid cash position.
AI Summary
Edgewise Therapeutics, Inc. filed its quarterly report for the period ending March 31, 2025. The company reported total assets of $95.1 million and total liabilities of $0.33 million for the quarter. Key financial figures include $95.2 million in total equity and $94.8 million in cash and cash equivalents. A subsequent event on April 3, 2025, is also noted.
Why It Matters
This filing provides a snapshot of Edgewise Therapeutics' financial health at the end of Q1 2025, crucial for investors assessing the company's stability and resources.
Risk Assessment
Risk Level: low — The filing is a standard quarterly report with no immediate red flags or significant negative financial events disclosed.
Key Numbers
- $95.1B — Total Assets (Financial position as of March 31, 2025)
- $0.33M — Total Liabilities (Financial position as of March 31, 2025)
- $95.2M — Total Equity (Financial position as of March 31, 2025)
- $94.8M — Cash and Cash Equivalents (Liquidity as of March 31, 2025)
Key Players & Entities
- Edgewise Therapeutics, Inc. (company) — Filer of the 10-Q report
- 20250331 (date) — End of the reporting period
- $95.1 million (dollar_amount) — Total assets as of March 31, 2025
- $0.33 million (dollar_amount) — Total liabilities as of March 31, 2025
- $95.2 million (dollar_amount) — Total equity as of March 31, 2025
- $94.8 million (dollar_amount) — Cash and cash equivalents as of March 31, 2025
- 20250403 (date) — Date of a subsequent event
FAQ
What were Edgewise Therapeutics' total assets as of March 31, 2025?
Edgewise Therapeutics reported total assets of $95.1 million as of March 31, 2025.
What was the company's total equity for the period ending March 31, 2025?
The company's total equity was $95.2 million for the period ending March 31, 2025.
What were the total liabilities reported in the Q1 2025 filing?
Total liabilities were reported as $0.33 million for the period ending March 31, 2025.
What is the amount of cash and cash equivalents as of March 31, 2025?
As of March 31, 2025, Edgewise Therapeutics had $94.8 million in cash and cash equivalents.
Was there any significant subsequent event noted after the reporting period?
Yes, a subsequent event was noted on April 3, 2025.
Filing Details
This Form 10-Q (Form 10-Q) was filed with the SEC on May 8, 2025 regarding Edgewise Therapeutics, Inc. (EWTX).